The changing role of pathology in breast cancer diagnosis and treatment

Pathobiology

Volumn 78, Issue 2, 2011, Pages 99-114

  Leong, Anthony S Y ^a   Zhuang, Zhengping ^b  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Biomarkers; Breast cancer; Drug discovery; Immunohistochemistry; Molecular technology; Predictive markers; Prognosis; Proteomics; Stem cells

Indexed keywords

BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; ESTROGEN RECEPTOR; LAPATINIB; MATRIX METALLOPROTEINASE INHIBITOR; OLAPARIB; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB;

BREAST CANCER; BREAST CARCINOMA; CANCER STEM CELL; CANCER SURVIVAL; COMPARATIVE GENOMIC HYBRIDIZATION; DRUG MECHANISM; GENE DOSAGE; GENE EXPRESSION SYSTEM; HUMAN; IMMUNOHISTOCHEMISTRY; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; UNSPECIFIED SIDE EFFECT;

BREAST NEOPLASMS; CARCINOMA, DUCTAL; COMPARATIVE GENOMIC HYBRIDIZATION; DRUG DISCOVERY; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASTIC STEM CELLS; PROGNOSIS; PROTEOMICS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79959303003     PISSN: 10152008     EISSN: 14230291     Source Type: Journal    
DOI: 10.1159/000292644     Document Type: Review

References (173)

1. Bloom HJ, Richardson WW: Histological grading and prognosis in breast cancer: a study of 1,409 cases of which 359 have been followed for 15 years. Br J Cancer 1957; 11: 359-377.
2. Blamey R: The design and clinical use of the Nottingham Prognostic Index in breast cancer. Breast 1996; 5: 156-157.
3. Boyages J, Chua B, Taylor R, et al: Use of the St Galen classification for patients with node-negative breast cancer may lead to overuse of adjuvant chemotherapy. Br J Surg 2002; 89: 789-796. (Pubitemid 34600976)
4. Goldhirsch A, Wood WC, Gelber RD, et al: Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003; 21: 3357-3365. (Pubitemid 46606270)
5. Adjuvant! online. http://www.adjuvantonline.com/index.jsp (accessed October 10, 2009).
6. Lipponen P, Aaltomaa S, Eskelinen M: The changing importance of prognostic factors in breast cancer during long-term follow-up. Int J Cancer 1992; 51: 698-702.
7. Decker T, Hungermann D, Bocker W: Prognostic and predictive factors of invasive breast cancer: update 2009 (in German). Pathologe 2009; 30: 49-55.
8. Leong AS, Lee AK: Leader: Biological indices in the assessment of breast cancer. Clin Mol Pathol 1995; 48:M221-M238.
9. McGuire WL: Breast cancer prognostic factors: evaluation guidelines. J Natl Cancer Inst 1990; 83: 154-155.
10. Harbeck N, Jakesz R: St Gallen 2007: breast cancer treatment consensus report. Breast Care 2007; 2: 130-134. (Pubitemid 47014392)
11. Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival - an overview of the randomized trials. Lancet 2005; 365: 1687-1717.
12. Ring AE, Smith IE, Ashley S, et al: Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer 2004; 91: 2012-2017. (Pubitemid 40128767)
13. Colleoni M, Viale G, Zahrieh D: Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 2004; 10: 6622-6628. (Pubitemid 39346559)
14. Dowsett M, Houghton J, Iden C: Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according to oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol 2006; 17: 818-826.
15. Dowsett M, Cuzick J, Wale C, et al: Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: a hypothesis-generating study. J Clin Oncol 2005; 23: 7512-7517. (Pubitemid 46291814)
16. Leong AS: Quantitation in immunohistology - fact or fiction? A discussion of factors that influence results. Appl Immunohistochem Mol Morphol 2004; 12: 1-7.
17. Leong TY, Leong AS: Variables that influence outcomes in immunohistology. Aust J Med Sci 2007; 28: 47-59. (Pubitemid 47014002)
18. Misdiagnosed: anatomy of Newfoundland's cancer testing scandal. http://www.cbc.ca/news/background/cancer/misdiagnosed.html# (accessed October 2009).
19. Wolff AC, Hammond EH, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145. (Pubitemid 350003059)
20. Leong AS: Pitfalls in diagnostic immunohistology. Adv Anat Pathol 2004; 11: 86-93.
21. Harvey JM, Clark GM, Osborne CK, Allred C: Estrogen receptor status by immunohistochemistry is superior to ligand-binding assay for endocrine response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 1474-1481. (Pubitemid 29220854)
22. Regitnig P, Reiner A, Dinges HP, et al: Quality assurance for detection of estrogen and progesterone receptors by immunohistochemistry in Austrian pathology laboratories. Virchows Arch 202; 441: 328-334.
23. Collins LC, Botero ML, Schnitt SJ: Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer: an analysis of 825 cases. Am J Clin Pathol 2005; 123: 16-20. (Pubitemid 40066167)
24. Nadji M, Gomez-Fernandez C, Ganjei-Azar P, Morales AR: Immunohistochemistry of estrogen and progesterone receptor reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol 2005; 123: 21-27. (Pubitemid 40066168)
25. Elledge RM, Osborne CK: Oestrogen receptors and breast cancer. Br Med J 1997; 314: 1843-1844. (Pubitemid 27263237)
26. Ross JS, Fletcher JA, Linette GP, et al: The Her2/gene and protein in breast cancer 2003: biomarker and target therapy. Oncologist 2003; 8: 307-325.
27. Carter P, Presta L, Gorman CM, et al: Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992; 89: 4285-4289.
28. Baselga J, Perez EA, Peinkowski T, Bell R: Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist 2006; 11(suppl 1):4-12.
29. Emens LA: Trustuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer. Am J Ther 2005; 12: 243-253.
30. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792. (Pubitemid 32222155)
31. Marty M, Cognetti F, Maraninchi D, et al: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005; 23: 4265-4274. (Pubitemid 46207001)
32. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684. (Pubitemid 41464706)
33. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-1672. (Pubitemid 41464705)
34. Leong TY, Leong AS: Controversies in the assessment of HER2: more questions than answers. Adv Anat Pathol 2006; 13: 263-270.
35. Leong AS, Haffajee Z, Clarke M: Microwave enhancement of CISH for Her2 oncogene. Appl Immunohistochem Mol Morphol 2007; 15: 88-93. (Pubitemid 46673323)
36. Pothos A, Plastiras A, Vlachodimitropoulos D, et al: Comparison of chromogenic in situ hybridization with fluorescence in situ hybridization and immunohistochemistry for the assessment of Her2/neu oncogene in archival material of breast carcinoma. Acta Histochem Cytochem 2008; 41: 59-64. (Pubitemid 351904792)
37. van de Vijver M, Bilous M, Hanna W, et al: Chromogenic in situ hybridization for the assessment of HER2 status in breast cancer: an international validation study. Breast Cancer Res 2007; 9:R68.
38. Bilous M, Morey A, Armes J, et al: Chromogenic in situ hybridization testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridization and immunohistochemistry. Pathology 2006; 38: 130-134.
39. Perou CM, Sorlie T, Elsen MB, et al: Molecular portraits of human breast tumors. Nature 2000; 406: 747-752.
40. Hu Z, Fan C, Oh DS, et al: The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006; 7: 96.
41. Cheang MCU, Chia SK, Voduc D, et al: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009; 101: 736-750.
42. Rakha EA, Reis-Filho JS, Ellis IO: Impact of basal-like breast carcinoma determination for a more specific therapy. Pathobiology 2008; 75: 95-103. (Pubitemid 351820727)
43. Mullins M, Perreard L, Quackenbush JF, et al: Agreement in breast cancer classification between microarray and quantitative reverse transcription PCR from fresh frozen and formalin-fixed, paraffin-embedded tissues. Clin Chem 2007; 53: 1273-1279. (Pubitemid 47020983)
44. Chanrion M, Fontaines H, Rodriguez C, et al: A new molecular breast cancer subclassification defined from a large scale real-time quantitative RT-PCR study. BMC Cancer 2007; 7: 39.
45. Abd El-Rehim DM, Ball G, Pinder SE, et al: High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analysis. Int J Cancer 2005; 116: 340-350. (Pubitemid 40993329)
46. Makretsov NA, Huntsman DG, Nielsen TO, et al: Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma. Clin Cancer Res 2004; 10: 6143-6151. (Pubitemid 39287520)
47. Dolled-Filhart M, Ryden L, Cregger M, et al: Classification of breast cancer using genetic algorithms and tissue microarrays. Clin Cancer Res 2006; 12: 6459-6468. (Pubitemid 44799719)
48. Raymond WA, Leong AS: Vimentin - a new prognostic parameter in breast carcinoma. J Pathol 1989; 158: 107-114. (Pubitemid 19157012)
49. Leong AS, Raymond WA: Update: prognostic parameters in breast carcinoma. Pathology 1989; 21: 169-175. (Pubitemid 20059772)
50. Dairkee SH, Ljung BM, Smith H, Hackett A: Immunolocalization of a human basal epithelium specific keratin in benign and malignant breast disease. Breast Cancer Res Treat 1987; 10: 11-20.
51. Santini D, Ceccarelli C, Taffurelli M, et al: Differentiation pathways in primary invasive breast carcinoma as suggested by intermediate filament and biopathological marker expression. J Pathol 1996; 179: 386-391. (Pubitemid 26276107)
52. Jumppanen M, Gruvberger-Saal S, Kauraniemi P, et al: Basal-like phenotype is not associated with patient survival in estrogen receptor-negative breast cancers. Breast Cancer Res 2007; 9:R16.
53. Pulford LG, Reis-Filho JS, Ryder K, et al: Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and longterm survival. Breast Cancer Res 2007; 9:R4.
54. Rouzier R, Perou CM, Symmans WF, et al: Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 11: 5678-5685. (Pubitemid 41170290)
55. Carey LA, Dees EC, Sawyer L, et al: The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007; 13: 2329-2334. (Pubitemid 46698581)
56. Dent R, Trudeau M, Pritchard KL, et al: Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429-4434. (Pubitemid 47219710)
57. Abd El-Rehim DM, Pinder SE, Paish CE, et al: Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 2004; 203: 661-671. (Pubitemid 38714103)
58. Rakha EA, Putti TC, Abd El-Rehim DM, et al: Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol 2006; 208: 495-506. (Pubitemid 43329336)
59. Banerjee S, Reis-Filho JS, Ashley S, et al: Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol 2006; 59: 729-735. (Pubitemid 44048783)
60. Jones C, Ford E, Gillett C, et al: Molecular cytogenetic identification of subgroups of grade III invasive ductal breast carcinomas with different clinical outcomes. Clin Cancer Res 2004; 10: 5988-5997. (Pubitemid 39287503)
61. Liedtke C, Mazouni C, Hess KR, et al: Response to neoadjuvant therapy and longterm survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26: 1275-1281.
62. Savage K, Lambros MB, Robertson D, et al: Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinoma: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res 2007; 13: 90-101. (Pubitemid 46121857)
63. Yehiely F, Moyano JV, Evans JR, et al: Deconstructing the molecular portrait of basal-like breast cancer. Trends Mol Med 2006; 12: 537-544. (Pubitemid 44740239)
64. Molokentin JD: The zinc finger containing transcription factors GATA-4, -5, and -6: ubiquitously expressed regulators of tissue specific gene expression. J Biol Chem 2000; 275: 38949-38952.
65. Sorlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874. (Pubitemid 32878711)
66. Sorlie T, Tibshirani R, Parker J, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100: 8418-8423. (Pubitemid 36842560)
67. Tirkkonen M, Johannsson O, Agnarsson BA, et al: Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res 1997; 57: 1222-1227. (Pubitemid 27152540)
68. Jonsson G, Naylor TL, Vallon-Christersson J, et al: Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization. Cancer Res 2005; 65: 7612-7621. (Pubitemid 41297233)
69. Parker J, Mullins M, Cheang MC, et al: A supervised risk predictor of breast cancer based on biological subtypes. J Clin Oncol 2008; 26(suppl 15):43s.
70. Perreard L, Fan C, Quackenbush JF, et al: Classification and risk stratification of invasive breast carcinomas using real-time quantitative RT-PCR assay. Breast Cancer Res 2006; 8:R23.
71. Calza S, Hall P, Auer G, et al: Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res 2006; 8:R34.
72. Fadare O, Tavassoli FA: The phenotypic spectrum of basal-like breast cancers: a critical appraisal. Adv Anat Pathol 2007; 14: 358-373. (Pubitemid 47312292)
73. Nielsen TO, Hsu FD, Jensen K, et al: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10: 5367-5374. (Pubitemid 39100473)
74. Cheang MC, Vodue D, Bajdik C, et al: Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008; 14: 1368-1376. (Pubitemid 351413917)
75. Tan DS, Marchio C, Jones RL, et al: Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat 2008; 111: 27-44. (Pubitemid 352009225)
76. Wirapati P, Sotiriou C, Kumkel S, et al: Metaanalysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008; 10:R65.
77. Kreike B, van Kouwenhove M, Horlings H, et al: Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 2007; 9:R65.
78. Weigelt B, Horlings HM, Kreike B, et al: Refinement of breast cancer classification by molecular characterization of histological specific types. J Pathol 2008; 216: 141-150.
79. Charpin C, Secq V, Giusiano S, et al: A signature predictive of disease outcome in breast carcinomas, identified by quantitative immunocytochemical assays. Int J Cancer 2008; 124: 2124-2134.
80. Jacquemier J, Ginestier C, Rougemont J, et al: Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res 2005; 65: 767-779. (Pubitemid 40216434)
81. Livasy CA, Karaca G, Nanda R, et al: Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006; 19: 264-271. (Pubitemid 43117611)
82. Reis-Filho JS, Tutt AN: Triple negative tumors: a critical review. Histopathology 2008; 52: 108-118. (Pubitemid 350265179)
83. Leong AS: Quantitative immunohistology: tissue section thickness, another glitch in the path to standardization. Appl Immunohistochem Mol Morphol 2009; 17: 465-469.
84. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN: Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007; 608: 1-22.
85. Petrelli A, Giordano S: From single- to multitarget drugs in cancer therapy: when a specificity becomes an advantage. Curr Med Chem 2008; 15: 422-432. (Pubitemid 351472408)
86. Brown PO, Botstein D: Exploring the new world of the genome with DNA microarrays. Nat Genet 1999; 21: 33-37. (Pubitemid 29031489)
87. Simon R, Radmacher D, Dobbin K, McShane LM: Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst 2003; 95: 14-18. (Pubitemid 36124291)
88. Huang E, Cheng SH, Dressman H, et al: Gene expression predictors of breast cancer outcomes. Lancet 2003; 361: 1590-1596. (Pubitemid 36578995)
89. Chen G, Gharib TG, Huang CC, et al: Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. Clin Cancer Res 2002; 8: 2290-2305.
90. Kumarathasan P, Mohottalage S, Goegan P, Vincent R: An optimized protein in-gel digestion method for reliable proteome characterization by MALDI-TOF-MS analysis. Anal Biochem 2005; 346: 85-89. (Pubitemid 41456629)
91. Meunier B, Bouley J, Piec I, et al: Data analysis methods for detection of differential protein expression in two-dimensional gel electrophoresis. Anal Biochem 2005; 340: 226-230. (Pubitemid 40544861)
92. Hanash S: 2-D or not 2-D - is there a future for 2-D gels in proteomics? Insights from the York proteomic meeting. Proteomics 2001; 1: 635-637.
93. Gorg A, Obermaier C, Boguth G, et al: The current state of two-dimensional electrophoresis with immobilized pH gradients. Electrophoresis 2000; 21: 1202-1209.
94. Bisca A, D'Ambrosio C, Scaloni A, et al: Proteomic evaluation of core biopsy specimens from breast lesions. Cancer Lett 2004; 204: 79-86. (Pubitemid 38117196)
95. Shen Y, Tolic N, Zhao R, et al: Ultrasensitive proteomics using high-efficiency on-line micro-SPE-naoLC-nanoESI MS and MS/MS. Anal Chem 2001; 21: 198-210.
96. Wang Y, Rudnick P, Evans E, Zhuang Z, et al: Proteome Analysis of microdissected tumor tissue using a capillary isoelectric focusing-based multidimensional separation platform coupled with ESI-tandem MS. Anal Chem 2005; 77: 6549-6556. (Pubitemid 41504436)
97. Celis JE, Gromov P, Cabezon T, et al: Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery. Mol Cell Proteomics 2004; 3: 327-344. (Pubitemid 38702087)
98. Somiari RI, Sullivan A, Russell S, et al: High-throughput proteomic analysis of human infiltrating ductal carcinoma. Proteomics 2003; 3: 1863-1873. (Pubitemid 37305880)
99. Zhuang Z, Bertheau P, Emmert-Buck M, et al: A microdissection technique for archival DNA analysis of specific cell populations in lesions less than one millimeter in size. Am J Pathol 1995; 146: 620-625.
100. Emmert-Buck MR, Bonner RF, Smith PD, et al: Laser capture microdissection. Science 1996; 274: 998-1001. (Pubitemid 26398425)
101. Wulfkuhle JD, Mclean KC. Pawetetz CP, et al: Proteomics of human breast ductal carcinoma in situ. Cancer Res 2002; 62: 6740-6747.
102. Stoeckli M, Chaurand P, Hallahan DE, Caprioli RM: Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues. Nat Med 2001; 7: 493-496. (Pubitemid 32298555)
103. Paweletz CP, Charboneau L, Bichsel VE, et al: Reverse phase protein microarrays which capture disease progression show activation of prosurvival pathways at the cancer invasion front. Oncogene 2001; 20: 1981-1989. (Pubitemid 32458030)
104. Liotta LA, Espina V, Mehta AI, et al: Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell 2003; 3: 317-325 (Pubitemid 38340301)
105. Torhorst J, Bucher C, Kononen J, et al: Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 2001; 159: 2249-2256. (Pubitemid 33104278)
106. Kallioniemi A, Kallioniemi OP, Sudar D, et al: Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 1992; 258: 818-821.
107. Weiss MM, Hermsen MA, Meijer GA, et al: Comparative genomic hybridization. Mol Pathol 1999; 52: 243-251.
108. Aubele M, Mattis A, Zitzelsberger H, et al: Extensive ductal carcinoma in situ with small foci of invasive ductal carcinoma: evidence of genetic resemblance by CGH. Int J Cancer 2000; 85: 82-86.
109. Buerger H, Simon R, Schafer KL, et al: Genetic relation of lobular carcinoma in situ, ductal carcinoma in situ, and associated invasive carcinoma of the breast. Mol Pathol 2000; 53: 118-121. (Pubitemid 30396450)
110. Cingoz S, Altungoz O, Canda T, et al: DNA copy number changes detected by comparative genomic hybridization and their association with clinicopathologic parameters in breast tumors. Cancer Genet Cytogenet 2003; 145: 108-114. (Pubitemid 36993740)
111. Jones C, Ford E, Gillett C, et al: Molecular cytogenetic identification of subgroups of grade III invasive ductal breast carcinomas with different clinical outcomes. Clin Cancer Res 2004; 10: 5988-5997. (Pubitemid 39287503)
112. Jones C, Damiani S, Wells D, et al: Molecular cytogenetic comparison of apocrine hyperplasia and apocrine carcinoma of the breast. Am J Pathol 2001; 158: 207-214. (Pubitemid 32096486)
113. Lage JM, Leamon JH, Pejovic T, et al: Whole genome analysis of genetic alterations in small DNA samples using hyperbranched strand displacement amplification and array-CGH. Genome Res 2003; 13: 294-307. (Pubitemid 36581838)
114. Solinas-Toldo S, Lampel S, Stilgenbauer S, et al: Matrix-based comparative genomic hybridization: biochips to screen for genomic imbalances. Genes Chromosomes Cancer 1997; 20: 399-407. (Pubitemid 27520090)
115. Pollack JR, Perou CM, Alizadeh AA, et al: Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nat Genet 1999; 23: 41-46. (Pubitemid 29418785)
116. Weaver Z, Montagna C, Xu X, et al: Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer. Oncogene 2002; 21: 5097-5107.
117. Jonsson G, Naylor TL, Vallon-Christersson J, et al: Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization. Cancer Res 2005; 65: 7612-7621. (Pubitemid 41297233)
118. Tirkkonen M, Kainu T, Loman N, et al: Somatic genetic alterations in BRCA2-associated and sporadic male breast cancer. Genes Chromosomes Cancer 1999; 24: 56-61. (Pubitemid 28544463)
119. Wessels LF, van Welsem T, Hart AA, et al: Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors. Cancer Res 2002; 62: 7110-7117. (Pubitemid 35424107)
120. van Beers EH, van Welsem T, Wessels LF, et al: Comparative genomic hybridization profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations. Cancer Res 2005; 65: 822-827. (Pubitemid 40216440)
121. Nyante SJ, DeVries S, Chen YY, Hwang ES: Array-based comparative genomic hybridization of ductal carcinoma in situ and synchronous invasive lobular cancer. Hum Pathol 2004; 35: 759-763. (Pubitemid 38881088)
122. Seo MY, Rha SY, Yang SH, et al: The pattern of gene copy number changes in bilateral breast cancer surveyed by cDNA microarray-based comparative genomic hybridization. Int J Mol Med 2004; 13: 17-24.
123. Rennstam K, Ahlstedt-Soini M, Baldetorp B, et al: Patterns of chromosomal imbalances defines subgroups of breast cancer with distinct clinical features and prognosis: a study of 305 tumors by comparative genomic hybridization. Cancer Res 2003; 63: 8861-8868. (Pubitemid 38064066)
124. Jones C, Ford E, Gillett C, et al: Molecular cytogenetic identification of subgroups of grade III invasive ductal breast carcinomas with different clinical outcomes. Clin Cancer Res 2004; 10: 5988-5997. (Pubitemid 39287503)
125. Van't Veer LJ, Dai H, van de Vijer MJ, et al: Gene expression profiling predicts clinical outcomes of breast cancer. Nature 2002; 415: 530-536.
126. Buyse M, Loi S, van't Veer LJ, et al: Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006; 98: 1183-1192. (Pubitemid 44390989)
127. Sparano JA, Paik S: Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 2008; 26: 721-728. (Pubitemid 351264384)
128. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-2826. (Pubitemid 40051905)
129. Paik S, Tang G, Shak S, et al: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24: 3726-3734. (Pubitemid 46622311)
130. Ma XJ, Hilsenback SG, Wang W, et al: The HOX-B13:IL17BR expression index is a prognostic factor in early stage breast cancer. J Clin Oncol 2006; 24: 4611-4619. (Pubitemid 46630959)
131. Wang Z, Dahiya S, Provencher H, et al: The prognostic biomarkers HOXB13, IL17BR and CHDH are regulated by estrogen in breast cancer. Clin Cancer Res 2007; 13: 6327-6334.
132. Ma XJ, Salunga R, Dahiya S, et al: A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin Cancer Res 2008; 14: 2601-2608.
133. Sotiriou C, Wirapati P, Loi S, et al: Comprehensive analysis integrating both clinicopathological and gene expression data in more than 1,500 samples: proliferation captured by gene expression grade index appears to be the strongest prognostic factor in breast cancer. J Clin Oncol 2006; 24: 4S.
134. Wang Y, Klijn JG, Zhang Y, et al: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005; 365: 671-679. (Pubitemid 40260888)
135. Loi S, Haibe-Kains B, Desmedi C, et al: Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 2007; 25: 1239-1246. (Pubitemid 46640570)
136. Desmedt C, Haibe-Kains B, Wirapati P, et al: Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 2008; 14: 5158-5165.
137. Finak G, Bertos N, Pepin F, et al: Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008; 14: 518-527. (Pubitemid 351655218)
138. Duffy MJ: Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies. Clin Chem 2002; 48: 1194-1197.
139. Eppenberger U, Kuang W, Schlaeppi JM, et al: Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients. J Clin Oncol 1998; 16: 3129-3136. (Pubitemid 28417436)
140. Janicke F, Prechit A, Thompsen C, et al: Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 2001; 93: 911-920.
141. Sudakin V, Yen TJ: Targeting mitosis for anti-cancer therapy. BioDrugs 2007; 21: 225-233. (Pubitemid 47104978)
142. Hidalgo M, Eckhardt SG: Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Can Inst 2001; 93: 178-193. (Pubitemid 32166488)
143. Pritchard KI, Messersmith H, Elavathil L, et al: HER-2 and topoisomerase II as predictors of response to chemotherapy. J Clin Oncol 2008; 26: 736-744. (Pubitemid 351264386)
144. Reid A, Vidal L, Shaw H, de Bono J: Dual inhibition of ErbB1 (EGFR/HER1)
145. Fong PC, Boss DS, Yap TA, et al: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-134.
146. Reya T, Morrison SJ, Clarke MF, Weissman IL: Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111. (Pubitemid 33041634)
147. Heppner GH: Tumor heterogeneity. Cancer Res 1984; 44, 2259-2265.
148. Nowell PC: Mechanisms of tumor progression. Cancer Res 1986; 46: 2203-2207.
149. Fialkow PJ: Clonal origin of human tumors. Biochim Biophys Acta 1976; 458: 283-321.
150. Sell S, Pierce GB: Maturation arrest of stem cell differentiation is a common pathway for the cellular origin of teratocarcinomas and epithelial cancers. Lab Invest 1994; 70: 6-22. (Pubitemid 24080100)
151. Al-Hajj M, Wicha SM, Benito-Hernandez A, et al: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-3988. (Pubitemid 36418143)
152. Honeth G, Bendahl PO, Ringnér M, et al: The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res 2008; 10:R53.
153. Ginestier C, Hur MH, Charafe-Jauffret E, et al: ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007; 1: 555-567. (Pubitemid 350056407)
154. Sakariassen PO, Immervoll H, Chekenya M: Cancer stem cells as mediators of treatment resistance in brain tumors: status and controversies. Neoplasia 2007; 9: 882-892. (Pubitemid 350086444)
155. Tang C, Chua CL, Ang BT: Insights into the cancer stem cell model of glioma tumorigenesis. Ann Acad Med Singapore 2007; 36: 352-357. (Pubitemid 47121450)
156. Kim M, Turnquist H, Jackson J, et al: The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells. Clin Cancer Res 2002; 8: 22-28. (Pubitemid 34101455)
157. Smalley MJ, Clarke RB: The mammary gland 'side population': a putative stem/ progenitor cell marker? J Mammary Gland Biol Neoplasia 2005; 10: 37-47.
158. Litingtung Y, Lawler AM, Sebald SM, et al: Growth retardation and neonatal lethality in mice with a homozygous deletion in the C-terminal domain of RNA polymerase II. Mol Gen Genet 1999; 261: 100-105. (Pubitemid 29137363)
159. Shafee N, Smith CR, Wei S, et al: Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res 2008; 68: 3243-3250.
160. Hambardzumyan D, Squatrito M, Holland EC: Radiation resistance and stem-like cells in brain tumors. Cancer Cell 2006; 10: 454-456. (Pubitemid 44854752)
161. Li X, Lewis MT, Huang J, et al: Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008; 100: 672-679.
162. Bast RC Jr, Kufe DW Jr, Pollock RE, et al: (eds) Cancer Medicine. Hamilton, Decker, 2000, pp 612-699.
163. Reddy A, Kaelin WG Jr: Using cancer genetics to guide the selection of anticancer drug targets. Curr Opin Pharmacol 2002; 2: 366-373. (Pubitemid 34830966)
164. Shawver LK, Slamon D, Ullrich A: Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 2002; 1: 117-123.
165. Brekke OH, Sandlie I: Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov 2003; 2: 52-62.
166. Kelloff GJ, Bast RC Jr, Coffey DS, et al: Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue. Clin Cancer Res 2004; 10: 3881-3884. (Pubitemid 38697624)
167. Garrett MD, Workman P: Discovering novel chemotherapeutic drugs for the third millennium. Eur J Cancer 1999; 35: 2010-2030. (Pubitemid 30026222)
168. Futreal PA, Kasprzyk A, Birney E, et al: Cancer and genomics. Nature 2001; 409: 850-852. (Pubitemid 32165342)
169. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954. (Pubitemid 34716871)
170. Marshall CJ: Opportunities for pharmacological intervention in the ras pathway. Ann Oncol 1995; 6(suppl 1):63-67.
171. Lundberg AS, Weinberg RA: Control of the cell cycle and apoptosis. Eur J Cancer 1999; 35: 1886-1894. (Pubitemid 30026210)
172. Vivanco I, Sawyers CL: The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501. (Pubitemid 37328931)
173. Workman P: New drug targets for genomic cancer therapy: successes, limitations, opportunities and future challenges. Curr Cancer Drug Targets 2001; 1: 33-47.